Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ADC Therapeutics SA Common Shares
(NY:
ADCT
)
3.935
-0.025 (-0.63%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ADC Therapeutics SA Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
The 3 Biotech Stocks That Could Make Your February Unforgettable
↗
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
↗
February 08, 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via
InvestorPlace
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Provides Business Updates
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Analyst Expectations for ADC Therapeutics's Future
↗
November 20, 2023
Via
Benzinga
The Latest Analyst Ratings for ADC Therapeutics
↗
September 12, 2023
Via
Benzinga
A Preview Of ADC Therapeutics's Earnings
↗
August 07, 2023
Via
Benzinga
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
4 Analysts Have This to Say About ADC Therapeutics
↗
July 25, 2023
Via
Benzinga
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
↗
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger...
Via
Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
October 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
↗
August 10, 2023
Via
Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
↗
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
↗
July 21, 2023
On Friday, 54 companies hit new 52-week lows.
Via
Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
↗
July 21, 2023
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...
Via
Benzinga
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
↗
July 11, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P...
Via
Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
July 11, 2023
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.
Via
Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
↗
July 11, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also...
Via
Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
↗
July 11, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
